These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
528 related articles for article (PubMed ID: 7828139)
1. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139 [TBL] [Abstract][Full Text] [Related]
2. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158 [TBL] [Abstract][Full Text] [Related]
3. The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic disease. Lotz JP; André T; Bouleuc C; Péne F; Gattegno B; Bazelly B; Houry S; Chapiro J; Selle F; Gligorov J; Izrael V Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S55-9. PubMed ID: 8899175 [No Abstract] [Full Text] [Related]
4. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321 [TBL] [Abstract][Full Text] [Related]
5. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C; J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987 [TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920 [TBL] [Abstract][Full Text] [Related]
7. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Droz JP; Biron P Cancer; 1995 Jul; 76(1):154-5. PubMed ID: 8630870 [No Abstract] [Full Text] [Related]
8. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561 [TBL] [Abstract][Full Text] [Related]
10. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Beyer J; Kingreen D; Krause M; Schleicher J; Schwaner I; Schwella N; Huhn D; Siegert W Cancer; 1997 Jan; 79(1):161-8. PubMed ID: 8988741 [TBL] [Abstract][Full Text] [Related]
11. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study. Tscherry G; Jacky E; Jost LM; Stahel RA Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168 [TBL] [Abstract][Full Text] [Related]
12. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046 [TBL] [Abstract][Full Text] [Related]
13. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Lotz JP; Bouleuc C; André T; Touboul E; Macovei C; Hannoun L; Lefranc JP; Houry S; Uzan S; Izrael V Cancer; 1996 Jun; 77(12):2550-9. PubMed ID: 8640705 [TBL] [Abstract][Full Text] [Related]
14. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438 [TBL] [Abstract][Full Text] [Related]
15. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. Lotz JP; Machover D; Malassagne B; Hingh B; Donsimoni R; Gumus Y; Gerota J; Lam Y; Tulliez M; Marsiglia H J Clin Oncol; 1991 Oct; 9(10):1860-70. PubMed ID: 1919636 [TBL] [Abstract][Full Text] [Related]
16. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687 [TBL] [Abstract][Full Text] [Related]
17. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593 [TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Lund B; Hansen OP; Hansen HH; Hansen M Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618 [TBL] [Abstract][Full Text] [Related]
20. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996]. Fléchon A; Biron P; Philip I; Blay JY; Droz JP Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]